title: Modulation of GITR for cancer immunotherapy.
abstract: Modulation of co-inhibitory and co-stimulatory receptors of the immune system has become a promising new approach for immunotherapy of cancer. With the recent FDA approval of CTLA-4 blockade serving as an important proof of principal, many new targets are now being translated into the clinic. Preclinical research has demonstrated that targeting glucocorticoid-induced tumor necrosis factor (TNF) receptor related gene (GITR), a member of TNF receptor superfamily, by agonist antibodies or natural ligand, can serve as an effective anti-tumor therapy. In this review, we will cover this research and the rationale that has led to initiation of two phase 1 clinical trials targeting GITR as a new immunotherapeutic approach for cancer.
authors.affiliation: Swim Across America Laboratory, Immunology Program, Sloan-Kettering Institute for Cancer Research, New York, NY, USA.
authors.forename: David A
authors.initials: DA
authors.lastname: Schaer
authors.forename: Judith T
authors.initials: JT
authors.lastname: Murphy
authors.forename: Jedd D
authors.initials: JD
authors.lastname: Wolchok
mesh_terms: D000818:Animals; D053450:Glucocorticoid-Induced TNFR-Related Protein / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D015854:Up-Regulation
chemical_list: D053450:Glucocorticoid-Induced TNFR-Related Protein